## Johann Steiner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3646045/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Long-term cortisol stress response in depression and comorbid anxiety is linked with reduced N-acetylaspartate in the anterior cingulate cortex. World Journal of Biological Psychiatry, 2023, 24, 34-45.	2.6	3
2	The many facets of CD26/dipeptidyl peptidase 4 and its inhibitors in disorders of the CNS– a critical overview. Reviews in the Neurosciences, 2023, 34, 1-24.	2.9	3
3	The role of microglia in neuropsychiatric disorders and suicide. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 929-945.	3.2	26
4	Testing for Thyroid Peroxidase and Antineuronal Antibodies in and. Methods in Molecular Biology, 2022, 2343, 203-213.	0.9	0
5	Reduced GABAergic neuropil and interneuron profiles in schizophrenia: Complementary analysis of disease course-related differences. Journal of Psychiatric Research, 2022, 145, 50-59.	3.1	3
6	Gender-specific elevation of plasma anthranilic acid in schizophrenia: Protection against glutamatergic hypofunction?. Schizophrenia Research, 2022, 243, 483-485.	2.0	2
7	Volatile organic compounds from exhaled breath in schizophrenia. World Journal of Biological Psychiatry, 2022, 23, 773-784.	2.6	4
8	Changes in leukocytes and CRP in different stages of major depression. Journal of Neuroinflammation, 2022, 19, 74.	7.2	12
9	Canonical insulin signaling is not significantly impaired in early stages of depression. European Archives of Psychiatry and Clinical Neuroscience, 2022, , 1.	3.2	0
10	Ribosomal DNA transcription is increased in the left nucleus accumbens of heroin-dependent males. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 1603-1609.	3.2	2
11	Reduced habenular volumes and neuron numbers in male heroin addicts: a post-mortem study. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 835-845.	3.2	8
12	AgNOR parameters of dorsal raphe nucleus neurons as a potential diagnostic tool which could aid the differentiation between suicidal and non-suicidal death. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 587-589.	3.2	0
13	Reduced ribosomal DNA transcription in the prefrontal cortex of suicide victims: consistence of new molecular RT-qPCR findings with previous morphometric data from AgNOR-stained pyramidal neurons. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 567-576.	3.2	5
14	Plasma Anthranilic Acid and Leptin Levels Predict HAM-D Scores in Depressed Women. International Journal of Tryptophan Research, 2021, 14, 117864692110164.	2.3	8
15	Epidemiology of suicide in the Tricity metropolitan area in northern Poland 1980–2009: Evidence of influence by political and socioeconomic changes. Forensic Science International: Reports, 2021, 3, 100219.	0.8	2
16	Potential Cross-Links of Inflammation With Schizophreniform and Affective Symptoms: A Review and Outlook on Autoimmune Encephalitis and COVID-19. Frontiers in Psychiatry, 2021, 12, 729868.	2.6	6
17	The implications of hypothalamic abnormalities for schizophrenia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 182, 107-120.	1.8	8
18	Molecular mimicry of NMDA receptors may contribute to neuropsychiatric symptoms in severe COVID-19 cases. Journal of Neuroinflammation, 2021, 18, 245.	7.2	38

#	Article	IF	CITATIONS
19	Polyamines and polyamine-metabolizing enzymes in schizophrenia: Current knowledge and concepts of therapy. World Journal of Psychiatry, 2021, 11, 1177-1190.	2.7	5
20	Innate Immune Cells and C-Reactive Protein in Acute First-Episode Psychosis and Schizophrenia: Relationship to Psychopathology and Treatment. Schizophrenia Bulletin, 2020, 46, 363-373.	4.3	46
21	Autoimmune encephalitis with psychosis: Warning signs, step-by-step diagnostics and treatment. World Journal of Biological Psychiatry, 2020, 21, 241-254.	2.6	48
22	Binding varicella zoster virus: an underestimated facet of insulin-degrading enzyme´s implication for Alzheimer´s disease pathology?. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 495-496.	3.2	11
23	A proteomic signature associated to atypical antipsychotic response in schizophrenia patients: a pilot study. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 127-134.	3.2	11
24	Ribosomal DNA transcription in prefrontal pyramidal neurons is decreased in suicide. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 859-867.	3.2	3
25	Association between altered hippocampal oligodendrocyte number and neuronal circuit structures in schizophrenia: a postmortem analysis. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 413-424.	3.2	9
26	Enhanced mitochondrial autophagy (mitophagy) in oligodendrocytes might play a role in white matter pathology in schizophrenia. Medical Hypotheses, 2020, 134, 109443.	1.5	11
27	Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. Lancet Psychiatry,the, 2020, 7, 93-108.	7.4	252
28	Association of thyroid peroxidase antibodies with anti-neuronal surface antibodies in health, depression and schizophrenia – Complementary linkage with somatic symptoms of major depression. Brain, Behavior, and Immunity, 2020, 90, 47-54.	4.1	13
29	S11. PLASMA LEPTIN AND ANTHRANILIC ACID IN SCHIZOPHRENIA PATIENTS: NEW BIOMARKERS OF PREDISPOSITION TO METABOLIC ABNORMALITIES. Schizophrenia Bulletin, 2020, 46, S34-S34.	4.3	10
30	Blood plasma proteomic modulation induced by olanzapine and risperidone in schizophrenia patients. Journal of Proteomics, 2020, 224, 103813.	2.4	8
31	Editorial: Back to the Future: On the Road Towards Precision Psychiatry. Frontiers in Psychiatry, 2020, 11, 112.	2.6	9
32	Autoimmune encephalitis as a differential diagnosis of schizophreniform psychosis: clinical symptomatology, pathophysiology, diagnostic approach, and therapeutic considerations. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 803-818.	3.2	59
33	From putative brain tumor marker to high cognitive abilities: Emerging roles of a disintegrin and metalloprotease (ADAM) 12 in the brain. Journal of Chemical Neuroanatomy, 2020, 109, 101846.	2.1	9
34	Increased densities of T and B lymphocytes indicate neuroinflammation in subgroups of schizophrenia and mood disorder patients. Brain, Behavior, and Immunity, 2020, 88, 497-506.	4.1	62
35	Changes in the blood plasma lipidome associated with effective or poor response to atypical antipsychotic treatments in schizophrenia patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 101, 109945.	4.8	18
36	SLC Solute Carrier Transporters and Neurodegenerative Disorders: Drawing Attention to Cationic Amino Acid Transporters 1 and 2. Clinical Psychopharmacology and Neuroscience, 2020, 18, 467-468.	2.0	2

#	Article	IF	CITATIONS
37	Measurement of a Surrogate Biomarker for Arginine Vasopressin Secretion in Association with Physiometric and Molecular Biomarkers of Aging. Methods in Molecular Biology, 2020, 2138, 251-262.	0.9	Ο
38	The hypothalamus and neuropsychiatric disorders: psychiatry meets microscopy. Cell and Tissue Research, 2019, 375, 243-258.	2.9	18
39	Plasma xanthurenic acid in a context of insulin resistance and obesity in schizophrenia. Schizophrenia Research, 2019, 211, 98-99.	2.0	9
40	Perineuronal oligodendrocytes in health and disease: the journey so far. Reviews in the Neurosciences, 2019, 31, 89-99.	2.9	12
41	Insulin-signaling abnormalities in drug-naÃ <sup>-</sup> ve first-episode schizophrenia: Transduction protein analyses in extracellular vesicles of putative neuronal origin. European Psychiatry, 2019, 62, 124-129.	0.2	30
42	Blood plasma high abundant protein depletion unintentionally carries over 100 proteins. Separation Science Plus, 2019, 2, 449-456.	0.6	4
43	Reduced volumes of the external and internal globus pallidus in male heroin addicts: a postmortem study. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 317-324.	3.2	11
44	Glucose homeostasis in major depression and schizophrenia: a comparison among drug-naÃ⁻ve first-episode patients. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 373-377.	3.2	19
45	Investigation of human plasma depletome from patients with schizophrenia. Revista Dos Trabalhos De Iniciação CientÃfica Da UNICAMP, 2019, , .	0.0	1
46	25. OLIGODENDROCYTE-BASED IMPAIRMENT OF BRAIN CONNECTIVITY AS TARGET FOR NEW TREATMENT STRATEGIES IN SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S40-S41.	4.3	0
47	Some notes on citrulline in the CNS. Clinical Nutrition, 2018, 37, 757.	5.0	1
48	Allostatic load is associated with psychotic symptoms and decreases with antipsychotic treatment in patients with schizophrenia and first-episode psychosis. Psychoneuroendocrinology, 2018, 90, 35-42.	2.7	47
49	Dipeptidyl peptidase IV, which probably plays important roles in Alzheimer disease (AD) pathology, is upregulated in AD brain neurons and associates with amyloid plaques. Neurochemistry International, 2018, 114, 55-57.	3.8	27
50	Reduced Density of DISC1 Expressing Astrocytes in the Dentate Gyrus but not in the Subventricular Zone in Schizophrenia. Neuropsychopharmacology, 2018, 43, 457-458.	5.4	5
51	Dysfunction of the blood-cerebrospinal fluid-barrier and N-methyl-d-aspartate glutamate receptor antibodies in dementias. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 483-492.	3.2	19
52	Oxidative stress in drug-naÃ <sup>-</sup> ve first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 129-143.	3.2	45
53	Total hypothalamic volume is reduced in postmortem brains of male heroin addicts. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 243-248.	3.2	10
54	Elemental fingerprinting of schizophrenia patient blood plasma before and after treatment with antipsychotics. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 565-570.	3.2	15

#	Article	IF	CITATIONS
55	Ketamine influences the locus coeruleus norepinephrine network, with a dependency on norepinephrine transporter genotype – a placebo controlled fMRI study. NeuroImage: Clinical, 2018, 20, 715-723.	2.7	29
56	Stress, Maltreatment, Inflammation, and Functional Brain Changes in Depression. , 2018, , 267-285.		0
5 <b>7</b>	Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients. Frontiers in Psychiatry, 2018, 9, 209.	2.6	21
58	A clinical approach to new-onset psychosis associated with immune dysregulation: the concept of autoimmune psychosis. Journal of Neuroinflammation, 2018, 15, 40.	7.2	62
59	Postmortem studies indicate altered cell chemical composition of the suprachiasmatic nucleus in mood disorders. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 871-872.	3.2	2
60	Microglia in the dorsal raphe nucleus plays a potential role in both suicide facilitation and prevention in affective disorders. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 403-415.	3.2	50
61	Application of Proteomic Techniques for Improved Stratification and Treatment of Schizophrenia Patients. Advances in Experimental Medicine and Biology, 2017, 974, 3-19.	1.6	7
62	The new field of â€~precision psychiatry'. BMC Medicine, 2017, 15, 80.	5.5	347
63	The Application of Multiplex Biomarker Techniques for Improved Stratification and Treatment of Schizophrenia Patients. Methods in Molecular Biology, 2017, 1546, 19-35.	0.9	7
64	A Clinical Study Protocol to Identify Serum Biomarkers Predictive of Response to Antipsychotics in Schizophrenia Patients. Advances in Experimental Medicine and Biology, 2017, 974, 245-250.	1.6	3
65	Evidence of neuroinflammation in subgroups of schizophrenia and mood disorder patients: A semiquantitative postmortem study of CD3 and CD20 immunoreactive lymphocytes in several brain regions. Neurology Psychiatry and Brain Research, 2017, 23, 2-9.	2.0	29
66	Insulin-regulated aminopeptidase immunoreactivity is abundantly present in human hypothalamus and posterior pituitary gland, with reduced expression in paraventricular and suprachiasmatic neurons in chronic schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 427-443.	3.2	14
67	Associations between SNPs and immune-related circulating proteins in schizophrenia. Scientific Reports, 2017, 7, 12586.	3.3	21
68	Assessment of Insulin Resistance Among Drug-Naive Patients With First-Episode Schizophrenia in the Context of Hormonal Stress Axis Activation. JAMA Psychiatry, 2017, 74, 968.	11.0	26
69	Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms. World Journal of Biological Psychiatry, 2017, 18, 330-356.	2.6	33
70	Temporal Dynamics of Antidepressant Ketamine Effects on Glutamine Cycling Follow Regional Fingerprints of AMPA and NMDA Receptor Densities. Neuropsychopharmacology, 2017, 42, 1201-1209.	5.4	57
71	8. Allostatic Load is Associated With Positive Symptoms in Schizophrenia and First-Episode Psychosis and Decreases With Antipsychotic Therapy. Schizophrenia Bulletin, 2017, 43, S9-S10.	4.3	0
72	Editorial: Minding Glial Cells in the Novel Understandings of Mental Illness. Frontiers in Cellular Neuroscience, 2017, 11, 48.	3.7	4

#	Article	IF	CITATIONS
73	In human brain ornithine transcarbamylase (OTC) immunoreactivity is strongly expressed in a small number of nitrergic neurons. Metabolic Brain Disease, 2017, 32, 2143-2147.	2.9	6
74	Serum S100B Is Related to Illness Duration and Clinical Symptoms in Schizophrenia—A Meta-Regression Analysis. Frontiers in Cellular Neuroscience, 2016, 10, 46.	3.7	21
75	Effect of MK-801 and Clozapine on the Proteome of Cultured Human Oligodendrocytes. Frontiers in Cellular Neuroscience, 2016, 10, 52.	3.7	35
76	Oligodendrocyte and Interneuron Density in Hippocampal Subfields in Schizophrenia and Association of Oligodendrocyte Number with Cognitive Deficits. Frontiers in Cellular Neuroscience, 2016, 10, 78.	3.7	37
77	Decreased ribosomal DNA transcription in dorsal raphe nucleus neurons is specific for suicide regardless of psychiatric diagnosis. Psychiatry Research, 2016, 241, 43-46.	3.3	6
78	Reduced oxytocin receptor gene expression and binding sites in different brain regions in schizophrenia: A post-mortem study. Schizophrenia Research, 2016, 177, 59-66.	2.0	58
79	Leptin in bipolar disorder: A systematic review and meta-analysis. European Psychiatry, 2016, 35, 1-7.	0.2	32
80	Nucleus Accumbens Deep Brain Stimulation for Alcohol Addiction – Safety and Clinical Long-term Results of a Pilot Trial. Pharmacopsychiatry, 2016, 49, 170-173.	3.3	76
81	Assessment of Pharmacological Treatment Quality: Comparison of Symptom-triggered vs. Fixed-schedule Alcohol Withdrawal in Clinical Practice. Pharmacopsychiatry, 2016, 49, 199-203.	3.3	4
82	Blood-based immune-endocrine biomarkers of treatment response inÂdepression. Journal of Psychiatric Research, 2016, 83, 249-259.	3.1	24
83	Decreased Oligodendrocyte and Neuron Number in Anterior Hippocampal Areas and the Entire Hippocampus in Schizophrenia: A Stereological Postmortem Study. Schizophrenia Bulletin, 2016, 42, S4-S12.	4.3	68
84	The brain as immunoprecipitator of serum autoantibodies against Nâ€Methylâ€Dâ€aspartate receptor subunit NR1. Annals of Neurology, 2016, 79, 144-151.	5.3	75
85	C-reactive protein concentrations across the mood spectrum in bipolar disorder: a systematic review and meta-analysis. Lancet Psychiatry,the, 2016, 3, 1147-1156.	7.4	169
86	Identification of an Immune-Neuroendocrine Biomarker Panel for Detection of Depression: A Joint Effects Statistical Approach. Neuroendocrinology, 2016, 103, 693-710.	2.5	12
87	Decreased ribosomal DNA transcription in dorsal raphe nucleus neurons differentiates between suicidal and non-suicidal death. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 217-224.	3.2	12
88	The brain as â€~immunoprecipitator' of serum autoantibodies directed against the NMDAR subunit NR1. Neurology Psychiatry and Brain Research, 2016, 22, 5.	2.0	0
89	Morphometric analysis of the cerebral expression of ATP-binding cassette transporter protein ABCB1 in chronic schizophrenia: Circumscribed deficits in the habenula. Schizophrenia Research, 2016, 177, 52-58.	2.0	28
90	Pretreatment levels of the fatty acid handling proteins H-FABP and CD36 predict response to olanzapine in recent-onset schizophrenia patients. Brain, Behavior, and Immunity, 2016, 52, 178-186.	4.1	26

#	Article	IF	CITATIONS
91	Towards a blood-based diagnostic panel for bipolar disorder. Brain, Behavior, and Immunity, 2016, 52, 49-57.	4.1	59
92	GABAergic system impairment in the hippocampus and superior temporal gyrus of patients with paranoid schizophrenia: A post-mortem study. Schizophrenia Research, 2016, 177, 10-17.	2.0	27
93	Increased density of DISC1-immunoreactive oligodendroglial cells in fronto-parietal white matter of patients with paranoid schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 495-504.	3.2	14
94	Bilaterally reduced claustral volumes in schizophrenia and major depressive disorder: a morphometric postmortem study. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 25-33.	3.2	28
95	Ribosomal DNA transcription in dorsal raphe nucleus neurons is increased in residual schizophrenia compared to depressed patients with affective disorders. Psychiatry Research, 2015, 230, 233-241.	3.3	4
96	Biological pathways modulated by antipsychotics in the blood plasma of schizophrenia patients and their association to a clinical response. NPJ Schizophrenia, 2015, 1, 15050.	3.6	23
97	Reply. Annals of Neurology, 2015, 77, 184-184.	5.3	4
98	Expression of HLA-DR, CD80, and CD86 inÂHealthy Aging and Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 177-184.	2.6	23
99	MK-801 treatment affects glycolysis in oligodendrocytes more than in astrocytes and neuronal cells: insights for schizophrenia. Frontiers in Cellular Neuroscience, 2015, 09, 180.	3.7	35
100	Reduced density of glutamine synthetase immunoreactive astrocytes in different cortical areas in major depression but not in bipolar I disorder. Frontiers in Cellular Neuroscience, 2015, 9, 273.	3.7	36
101	Calretinin and parvalbumin in schizophrenia and affective disorders: a mini-review, a perspective on the evolutionary role of calretinin in schizophrenia, and a preliminary post-mortem study of calretinin in the septal nuclei. Frontiers in Cellular Neuroscience, 2015, 9, 393.	3.7	12
102	Stereological investigation of the posterior hippocampus in affective disorders. Journal of Neural Transmission, 2015, 122, 1019-1033.	2.8	25
103	Differential regional and cellular distribution of TFF3 peptide in the human brain. Amino Acids, 2015, 47, 1053-1063.	2.7	15
104	N-Methyl-d-aspartate receptor autoantibodies in schizophrenia and affective disorders. Schizophrenia Research, 2015, 162, 291.	2.0	6
105	Antineuronal Antibodies Against Neurotransmitter Receptors and Synaptic Proteins in Schizophrenia: Current Knowledge and Clinical Implications. CNS Drugs, 2015, 29, 197-206.	5.9	23
106	Decreased quinolinic acid in the hippocampus of depressive patients: evidence for local anti-inflammatory and neuroprotective responses?. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 321-329.	3.2	65
107	Possible sources and functions of l-homoarginine in the brain: review of the literature and own findings. Amino Acids, 2015, 47, 1729-1740.	2.7	22
108	Ribosomal DNA transcription in the dorsal raphe nucleus is increased in residual but not in paranoid schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 117-126.	3.2	12

#	Article	IF	CITATIONS
109	Preexisting Serum Autoantibodies Against the NMDAR Subunit NR1 Modulate Evolution of Lesion Size in Acute Ischemic Stroke. Stroke, 2015, 46, 1180-1186.	2.0	79
110	Postmortem volumetric analysis of the nucleus accumbens in male heroin addicts: implications for deep brain stimulation. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 647-653.	3.2	22
111	Investigation of molecular serum profiles associated with predisposition to antipsychotic-induced weight gain. World Journal of Biological Psychiatry, 2015, 16, 22-30.	2.6	20
112	Glial cells as key players in schizophrenia pathology: recent insights and concepts of therapy. Schizophrenia Research, 2015, 161, 4-18.	2.0	166
113	Downregulation of Neuregulin 1-ErbB4 Signaling and Antidepressant Properties of Ketamine: ErbB4 Expressing Pyramidal Neurons May Play a Role. Journal of Molecular Neuroscience, 2015, 55, 372-373.	2.3	1
114	Differential distribution of Y-box-binding protein 1 and cold shock domain protein A in developing and adult human brain. Brain Structure and Function, 2015, 220, 2235-2245.	2.3	9
115	VGF expression by T lymphocytes in patients with Alzheimer's disease. Oncotarget, 2015, 6, 14843-14851.	1.8	20
116	Clozapine promotes glycolysis and myelin lipid synthesis in cultured oligodendrocytes. Frontiers in Cellular Neuroscience, 2014, 8, 384.	3.7	45
117	Proteomic changes in serum of first onset, antidepressant drug-naÃ⁻ve major depression patients. International Journal of Neuropsychopharmacology, 2014, 17, 1599-1608.	2.1	91
118	Prevalence of <i>N</i> -Methyl-D-Aspartate Receptor Autoantibodies in the Peripheral Blood. JAMA Psychiatry, 2014, 71, 838.	11.0	73
119	ZNF804A Protein Is Widely Expressed in Human Brain Neurons: Possible Implications on Normal Brain Structure and Pathomorphologic Changes in Schizophrenia. Schizophrenia Bulletin, 2014, 40, 499-500.	4.3	9
120	The Role of Dopamine in Schizophrenia from a Neurobiological and Evolutionary Perspective: Old Fashioned, but Still in Vogue. Frontiers in Psychiatry, 2014, 5, 47.	2.6	273
121	Identification of Subgroups of Schizophrenia Patients With Changes in Either Immune or Growth Factor and Hormonal Pathways. Schizophrenia Bulletin, 2014, 40, 787-795.	4.3	84
122	S100B is downregulated in the nuclear proteome of schizophrenia corpus callosum. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 311-316.	3.2	18
123	Seroprevalence of autoantibodies against brain antigens in health and disease. Annals of Neurology, 2014, 76, 82-94.	5.3	301
124	Absence of dopamine receptor serum autoantibodies in schizophrenia patients with an acute disease episode. Schizophrenia Research, 2014, 158, 272-274.	2.0	10
125	Distribution of immunoreactive glutamine synthetase in the adult human and mouse brain. Qualitative and quantitative observations with special emphasis on extra-astroglial protein localization. Journal of Chemical Neuroanatomy, 2014, 61-62, 33-50.	2.1	34
126	Seroprevalence of n-methyl-d-aspartate glutamate receptor (NMDA-R) autoantibodies in aging subjects without neuropsychiatric disorders and in dementia patients. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 545-550.	3.2	55

#	Article	IF	CITATIONS
127	Increased densities of nitric oxide synthase expressing neurons in the temporal cortex and the hypothalamic paraventricular nucleus of polytoxicomanic heroin overdose victims: Possible implications for heroin neurotoxicity. Acta Histochemica, 2014, 116, 182-190.	1.8	26
128	Further evidence for a role of S100B in mood disorders: A human gene expression mega-analysis. Journal of Psychiatric Research, 2014, 53, 84-86.	3.1	14
129	Nardilysin, ADAM10, and Alzheimer's disease: of mice and men. Neurobiology of Aging, 2014, 35, e1.	3.1	92
130	Reduced microglial immunoreactivity for endogenous NMDA receptor agonist quinolinic acid in the hippocampus of schizophrenia patients. Brain, Behavior, and Immunity, 2014, 41, 59-64.	4.1	42
131	Decrease of serum S100B during an oral glucose tolerance test correlates inversely with the insulin response. Psychoneuroendocrinology, 2014, 39, 33-38.	2.7	11
132	Immune system and glucose metabolism interaction in schizophrenia: A chicken–egg dilemma. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 48, 287-294.	4.8	66
133	Age-related increase of VGF-expression in T lymphocytes. Aging, 2014, 6, 440-453.	3.1	17
134	Agmatinase and human cationic amino acid transporter 1 in mood disorder: what´s under the microscope?. Jnbs, 2014, 1, 67.	0.2	4
135	Correction: Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission?. Journal of Neuroinflammation, 2013, 10, .	7.2	2
136	Decreased expression of nardilysin in SH-SY5Y cells under ethanol stress andÂreduced density of nardilysin-expressing neurons in brains of alcoholics. Journal of Psychiatric Research, 2013, 47, 343-349.	3.1	3
137	Ribosomal DNA transcription in the anterior cingulate cortex is decreased in unipolar but not bipolar I depression. Psychiatry Research, 2013, 210, 338-345.	3.3	7
138	S100B-immunopositive astrocytes and oligodendrocytes in the hippocampus are differentially afflicted in unipolar and bipolar depression: A postmortem study. Journal of Psychiatric Research, 2013, 47, 1694-1699.	3.1	92
139	Wide distribution of CREM immunoreactivity in adult and fetal human brain, with an increased expression in dentate gyrus neurons of Alzheimer's as compared to normal aging brains. Amino Acids, 2013, 45, 1373-1383.	2.7	5
140	Deep brain stimulation of the nucleus accumbens for the treatment of addiction. Annals of the New York Academy of Sciences, 2013, 1282, 119-128.	3.8	106
141	Increased nuclear Olig1-expression in the pregenual anterior cingulate white matter of patients with major depression: A regenerative attempt to compensate oligodendrocyte loss?. Journal of Psychiatric Research, 2013, 47, 1069-1079.	3.1	34
142	Heart Failure—An Identified but Largely Ignored Source of Errors in Postmortem Brain Volume Studies. Journal of Cardiac Failure, 2013, 19, 600.	1.7	2
143	Increased density of AKAP5-expressing neurons in the anterior cingulate cortex of subjects with bipolar disorder. Journal of Psychiatric Research, 2013, 47, 699-705.	3.1	11
144	Disease severity is correlated to tract specific changes of fractional anisotropy in MD and CM thalamus—A DTI study in major depressive disorder. Journal of Affective Disorders, 2013, 149, 116-128.	4.1	36

#	Article	IF	CITATIONS
145	Hippocampal CA1 deformity is related to symptom severity and antipsychotic dosage in schizophrenia. Brain, 2013, 136, 804-814.	7.6	81
146	Concerning <scp>HB</scp> â€ <scp>EGF</scp> Brain Levels in Schizophrenia: Cellular Distribution of Putative Sheddases May Matter. CNS Neuroscience and Therapeutics, 2013, 19, 136-137.	3.9	4
147	Distinct structural alterations independently contributing to working memory deficits and symptomatology in paranoid schizophrenia. Cortex, 2013, 49, 1063-1072.	2.4	26
148	The human oligodendrocyte proteome. Proteomics, 2013, 13, 3548-3553.	2.2	24
149	Some notes on insulin-regulated aminopeptidase in depression. International Journal of Neuropsychopharmacology, 2013, 16, 1877-1878.	2.1	4
150	Increased Prevalence of Diverse N -Methyl-D-Aspartate Glutamate Receptor Antibodies in Patients With an Initial Diagnosis of Schizophrenia. JAMA Psychiatry, 2013, 70, 271.	11.0	336
151	Distinct Molecular Phenotypes in Male and Female Schizophrenia Patients. PLoS ONE, 2013, 8, e78729.	2.5	48
152	Integration of ultra-high field MRI and histology for connectome based research of brain disorders. Frontiers in Neuroanatomy, 2013, 7, 31.	1.7	24
153	Os possÃveis papéis da S100B na esquizofrenia. Revista De Psiquiatria Clinica, 2013, 40, 35-40.	0.6	3
154	Serum S100B Represents a New Biomarker for Mood Disorders. Current Drug Targets, 2013, 14, 1237-1248.	2.1	91
155	Disruption of Glutamate-Glutamine-GABA Cycle Significantly Impacts on Suicidal Behaviour: Survey of the Literature and Own Findings on Glutamine Synthetase CNS and Neurological Disorders - Drug Targets, 2013, 12, 900-913.	1.4	40
156	Volumetric Analysis of the Hypothalamus, Amygdala and Hippocampus in Non-Suicidal and Suicidal Mood Disorder Patients – A Post-Mortem Study. CNS and Neurological Disorders - Drug Targets, 2013, 12, 914-920.	1.4	32
157	Postmortem-Assessed Impairment of Neuronal Activity in Depression: The Dominant Impact of Suicide. CNS and Neurological Disorders - Drug Targets, 2013, 12, 930-935.	1.4	5
158	Possible Impact of Microglial Cells and the Monocyte-Macrophage System on Suicidal Behavior. CNS and Neurological Disorders - Drug Targets, 2013, 12, 971-979.	1.4	31
159	Reduced density of hypothalamic VGF-immunoreactive neurons in schizophrenia: a potential link to impaired growth factor signaling and energy homeostasis. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 365-374.	3.2	23
160	A postmortem assessment of mammillary body volume, neuronal number and densities, and fornix volume in subjects with mood disorders. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 637-646.	3.2	32
161	Differences between unipolar and bipolar I depression in the quantitative analysis of glutamic acid decarboxylase-immunoreactive neuropil. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 647-655.	3.2	16
162	Agmatinase, an inactivator of the putative endogenous antidepressant agmatine, is strongly upregulated in hippocampal interneurons of subjects with mood disorders. Neuropharmacology, 2012, 62, 237-246.	4.1	50

#	Article	IF	CITATIONS
163	Increased S100B+ NK cell counts in acutely ill schizophrenia patients are correlated with the free cortisol index, but not with S100B serum levels. Brain, Behavior, and Immunity, 2012, 26, 564-567.	4.1	16
164	The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. Journal of Leukocyte Biology, 2012, 92, 959-975.	3.3	293
165	Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: Further evidence for disease course-related immune alterations?. Brain, Behavior, and Immunity, 2012, 26, 1273-1279.	4.1	165
166	Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: Potential role of glial NMDA receptor modulators and impaired blood–brain barrier integrity. World Journal of Biological Psychiatry, 2012, 13, 482-492.	2.6	130
167	Molecular Sex Differences in Human Serum. PLoS ONE, 2012, 7, e51504.	2.5	26
168	Preferential networks of the mediodorsal nucleus and centromedian–parafascicular complex of the thalamus—A DTI tractography study. Human Brain Mapping, 2012, 33, 2627-2637.	3.6	75
169	Increased Density of Prohibitin-Immunoreactive Oligodendrocytes in the Dorsolateral Prefrontal White Matter of Subjects with Schizophrenia Suggests Extraneuronal Roles for the Protein in the Disease. NeuroMolecular Medicine, 2012, 14, 270-280.	3.4	25
170	Immunohistochemical evidence for impaired nitric oxide signaling of the locus coeruleus in bipolar disorder. Brain Research, 2012, 1459, 91-99.	2.2	17
171	Validating Serum S100B and Neuron-Specific Enolase as Biomarkers for the Human Brain – A Combined Serum, Gene Expression and MRI Study. PLoS ONE, 2012, 7, e43284.	2.5	62
172	Schizophrene Störungen. , 2012, , 297-313.		0
173	Reduction of gyrification index in the cerebellar vermis in schizophrenia: A post-mortem study. World Journal of Biological Psychiatry, 2011, 12, 99-103.	2.6	15
174	S100B protein in neurodegenerative disorders. Clinical Chemistry and Laboratory Medicine, 2011, 49, 409-424.	2.3	113
175	Human CD8+ T cells and NK cells express and secrete S100B upon stimulation. Brain, Behavior, and Immunity, 2011, 25, 1233-1241.	4.1	53
176	Do elevated glucocorticoids contribute to reduced cerebral expression of insulin-degrading enzyme in schizophrenia?. Journal of Psychiatric Research, 2011, 45, 1655-1656.	3.1	1
177	Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology, 2011, 36, 1092-1096.	2.7	130
178	Glial pathology is modified by age in mood disorders — A systematic meta-analysis of serum S100B in vivo studies. Journal of Affective Disorders, 2011, 134, 32-38.	4.1	55
179	A morphometric analysis of the septal nuclei in schizophrenia and affective disorders: reduced neuronal density in the lateral septal nucleus in bipolar disorder. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 47-58.	3.2	26
180	Protective effects of haloperidol and clozapine on energy-deprived OLN-93 oligodendrocytes. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 477-482.	3.2	21

2

#	Article	IF	CITATIONS
181	Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: Evidence for an immune-modulated glutamatergic neurotransmission?. Journal of Neuroinflammation, 2011, 8, 94.	7.2	466
182	Increased density of GAD65/67 immunoreactive neurons in the posterior subiculum and parahippocampal gyrus in treated patients with chronic schizophrenia. World Journal of Biological Psychiatry, 2011, 12, 57-65.	2.6	24
183	Oestrogen Downregulates BACE Protein in Human Cell Culture: What Does This Teach Us about Alzheimer's Disease?. Neurodegenerative Diseases, 2011, 8, 153-154.	1.4	3
184	Nitric Oxide and Schizophrenia: Present Knowledge and Emerging Concepts of Therapy. CNS and Neurological Disorders - Drug Targets, 2011, 10, 792-807.	1.4	45
185	Acute schizophrenia is accompanied by reduced T cell and increased B cell immunity. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 509-518.	3.2	95
186	The role of hippocampus dysfunction in deficient memory encoding and positive symptoms in schizophrenia. Psychiatry Research - Neuroimaging, 2010, 183, 187-194.	1.8	53
187	S100B serum levels are closely correlated with body mass index: An important caveat in neuropsychiatric research. Psychoneuroendocrinology, 2010, 35, 321-324.	2.7	96
188	Demonstration of disturbed activity of the lateral amygdaloid nucleus projection neurons in depressed patients by the AgNOR staining method. Journal of Affective Disorders, 2010, 126, 402-410.	4.1	12
189	Validation of a Blood-Based Laboratory Test to Aid in the Confirmation of a Diagnosis of Schizophrenia. Biomarker Insights, 2010, 5, BMI.S4877.	2.5	137
190	S100B Serum Levels in Schizophrenia Are Presumably Related to Visceral Obesity and Insulin Resistance. Cardiovascular Psychiatry and Neurology, 2010, 2010, 1-11.	0.8	27
191	Mood Disorders Are Glial Disorders: Evidence from In Vivo Studies. Cardiovascular Psychiatry and Neurology, 2010, 2010, 1-7.	0.8	61
192	Reduced density of ADAM 12-immunoreactive oligodendrocytes in the anterior cingulate white matter of patients with schizophrenia. World Journal of Biological Psychiatry, 2010, 11, 556-566.	2.6	36
193	Glutamatergic and resting state functional connectivity correlates of severity in major depression - the role of pregenual anterior cingulate cortex and anterior insula. Frontiers in Systems Neuroscience, 2010, 4, .	2.5	150
194	Schizophrenia, sleep disturbances and the suprachiasmatic nucleus: Reduced nitric oxide synthase may matter. Medical Hypotheses, 2010, 74, 397-398.	1.5	4
195	Haloperidol and clozapine decrease S100B release from glial cells. Neuroscience, 2010, 167, 1025-1031.	2.3	46
196	Association between paternal schizophrenia and low birthweight: ADAM12 may matter. Asian Journal of Andrology, 2010, 12, 453-454.	1.6	1
197	The Hypothalamus in Schizophrenia Research: No Longer a Wallflower Existence~!2009-12-09~!2010-02-07~!2010-08-09~!. Open Neuroendocrinology Journal (Online), 2010, 3, 59-67.	0.4	13

198 What Protects Patients with Schizophrenia from Developing Alzheimer Pathology?. , 2010, , 45-66.

#	Article	IF	CITATIONS
199	Brain abnormalities in schizophrenia. Medical Psychiatry, 2009, , 87-104.	0.2	1
200	Reduced neuronal expression of insulin-degrading enzyme in the dorsolateral prefrontal cortex of patients with haloperidol-treated, chronic schizophrenia. Journal of Psychiatric Research, 2009, 43, 1095-1105.	3.1	23
201	Dopamine–glutamate abnormalities in the frontal cortex associated with the catechol-O-methyltransferase (COMT) in schizophrenia. Brain Research, 2009, 1269, 166-175.	2.2	22
202	Suicide and depression in the quantitative analysis of glutamic acid decarboxylase-Immunoreactive neuropil. Journal of Affective Disorders, 2009, 113, 45-55.	4.1	37
203	Demonstration of disturbed activity of orbitofrontal pyramidal neurons in depressed patients by the AgNOR staining method. Journal of Affective Disorders, 2009, 118, 131-138.	4.1	13
204	Demonstration of disturbed activity of external globus pallidus projecting neurons in depressed patients by the AgNOR staining method. Journal of Affective Disorders, 2009, 119, 149-155.	4.1	14
205	Reduced neuronal co-localisation of nardilysin and the putative α-secretases ADAM10 and ADAM17 in Alzheimer's disease and Down syndrome brains. Age, 2009, 31, 11-25.	3.0	20
206	A New Pathophysiological Aspect of S100B in Schizophrenia: Potential Regulation of S100B by Its Scavenger Soluble RAGE. Biological Psychiatry, 2009, 65, 1107-1110.	1.3	59
207	Clial cells in schizophrenia: pathophysiological significance and possible consequences for therapy. Expert Review of Neurotherapeutics, 2009, 9, 1059-1071.	2.8	178
208	Tyrosine hydroxylase immunoreactivity in the locus coeruleus is elevated in violent suicidal depressive patients. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 513-520.	3.2	27
209	Demonstration of decreased activity of dorsal raphe nucleus neurons in depressed suicidal patients by the AgNOR staining method. Journal of Affective Disorders, 2008, 111, 251-260.	4.1	32
210	Immunological aspects in the neurobiology of suicide: Elevated microglial density in schizophrenia and depression is associated with suicide. Journal of Psychiatric Research, 2008, 42, 151-157.	3.1	678
211	S100B-immunopositive glia is elevated in paranoid as compared to residual schizophrenia: A morphometric study. Journal of Psychiatric Research, 2008, 42, 868-876.	3.1	94
212	The volumes of the fornix in schizophrenia and affective disorders: A post-mortem study. Psychiatry Research - Neuroimaging, 2008, 164, 265-273.	1.8	20
213	Beacon-like/ubiquitin-5-like immunoreactivity is highly expressed in human hypothalamus and increased in haloperidol-treated schizophrenics and a rat model of schizophrenia. Psychoneuroendocrinology, 2008, 33, 340-351.	2.7	13
214	Regional and cellular distribution patterns of insulin-degrading enzyme in the adult human brain and pituitary. Journal of Chemical Neuroanatomy, 2008, 35, 216-224.	2.1	22
215	S100B is expressed in, and released from, OLN-93 oligodendrocytes: Influence of serum and glucose deprivation. Neuroscience, 2008, 154, 496-503.	2.3	65
216	Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neuroscience, 2007, 8, 2.	1.9	223

#	Article	IF	CITATIONS
217	Dysregulation of GABAergic Neurotransmission in Mood Disorders: A Postmortem Study. Annals of the New York Academy of Sciences, 2007, 1096, 157-169.	3.8	77
218	Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization. Acta Neuropathologica, 2006, 112, 305-316.	7.7	199